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Abstract
Melatonin has anticarcinogenic properties in experimental models. We undertook a
case–cohort study of 928 Icelandic menwithout prostate cancer (PCa) nested within the
Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the pro-
spective association between ﬁrst morning-void urinary 6-sulfatoxymelatonin (aMT6s)
levels and the subsequent risk for PCa, under the hypothesis that menwith lower aMT6s
levels have an increased risk for advanced PCa. We used weighted Cox proportional
hazards models to assess the association between ﬁrst morning-void aMT6s levels and
PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with
incident PCa, including 24 with advanced disease. Men who reported sleep problems at
baseline had lower morning aMT6s levels compared with those who reported no sleep
problems. Menwithmorning aMT6s levels below themedian had a fourfold statistically
signiﬁcant increased risk for advanced disease comparedwithmenwith levels above the
median (hazard ratio: 4.04; 95% conﬁdence interval, 1.26–12.98). These results require
replication in larger prospective studies with longer follow-up.
Patient summary: In this report, we evaluated the prospective association between
urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower
levels of aMT6s were associated with an increased risk for advanced PCa.
# 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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E U RO P E AN URO LOG Y 6 7 ( 2 0 1 5 ) 1 9 1 – 1 9 4192The circadian rhythm regulates diverse physiologic and
metabolic activities [1]. Melatonin is a hormone secreted by
the pineal gland in a 24-h circadian rhythm; under normal
conditions, production peaks at night. Melatonin secretion
can be inhibited by many factors, including light exposure
at night. Most epidemiologic studies support a positive
association between measures of circadian disruption or
sleep loss and prostate cancer (PCa) risk [2]. In experimental
studies,melatonin exhibits chemopreventive properties [3].
Cross-sectionally, men with PCa had lower melatonin levels
compared with men with benign prostatic hyperplasia [4].
No prior study has evaluated the prospective association
betweenprediagnostic 6-sulfatoxymelatonin (aMT6s) levels,
the primary melatonin metabolite in urine, and PCa [5].
We undertook a case–cohort study (Supplemental Fig. 1)
within the Age, Gene/Environment Susceptibililty-Reykjavik
(AGES-Reykjavik) study to investigate the association
between morning urinary aMT6s levels and PCa risk. We
leveraged questionnaire data on sleep disruption, previously
linked with PCa risk [6], to investigate cross-sectional
associations with aMT6s levels.
Full study methods are provided in the online Supple-
ment. Briefly, AGES-Reykjavik collected information via
physical examination, questionnaire, and biologic speci-
mens during a 2-day assessment between 2002 and 2006.
Subjects collected a first morning-void urine sample. Urine
samples were assayed for aMT6s using the melatonin-
sulfate enzyme-linked immunosorbent assay (IBL Interna-
tional, Toronto, ON, Canada).
PCa diagnosis and cause of death were identified by
linkage with the nationwide Icelandic Cancer Registry and
Statistics Iceland using unique identification numbers. We
studied risk for total PCa, advanced cancer (extraprostatic[(Fig._1)TD$FIG]0%
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Fig. 1 – Percent of people in each sleep disruption category with low 6-sulfato
(AGES)-Reykjavik case–cohort study.
*In men without sleep problems (n = 309), the distribution of aMT6s was as fo
11.1 ng/ml, and 10th percentile = 6.5 ng/ml.
**Low aMT6s: aMT6s levels below the 25th percentile in men without sleep pr
y Number of men with low aMT6s levels (ie, <11.1 ng/ml).stage T3a or higher, N1/M1, cancer death), and lethal cancer
(N1/M1 or cancer death).
Participant characteristics were summarized by aMT6s
levels dichotomized at the subcohort median. We used Cox
proportional hazards regression, modified for the case–
cohort design using the Prentice method to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) for the
association between aMT6s levels and incident PCa. Models
were adjusted for age and creatinine levels, and additionally
for family history of PCa, beta-blocker use, depression, sleep
problems, and diabetes. Results were similar when addi-
tionally adjusted for cortisol.
Men with lower aMT6s levels tended to drink less
alcohol and had slightly lower creatinine levels, but were
more likely to have diabetes and to be taking beta-blockers
or psychotropic drugs (Supplemental Table 1). There were
no material differences in season of urine collection.
aMT6s levels were lower among men who reported sleep
problems compared to men without problems (Supple-
mental Table1).Wedetermined the25thpercentile of aMT6s
in men without sleep problems and defined values less than
the 25th percentile as low. Twenty-five percent of men
without sleep problems had low aMT6s levels (Fig. 1). In
contrast, 35% ofmen takingmedications for sleep and 34% of
men with severe sleep problems had low aMT6s levels.
Men with aMT6s levels below the median had a 47%
higher, although not statistically significant, PCa risk overall
compared to men with higher levels (Table 1). Men with
lower aMT6s levels had a fourfold increased risk for
advanced disease (HR: 4.04; 95% CI, 1.26–12.98); results
were similar for lethal PCa (Table 1). In subanalyses to
consider potential biases (Supplemental Table 3), including
limiting analyses to men who returned their urine samplesg Problems staying
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Table 1 – Association between 6-sulfatoxymelatonin levels and risk of prostate cancer: Age, Gene/Environment Susceptibility (AGES)-
Reykjavik case–cohort study 2002–2009
High Low* p value
Overall PCa, no.
PCa cases/subcohort control participants 52/432 59/432 –
HR (95% CI)
Age and creatinine level adjusted Ref. 1.31 (0.85–2.04) 0.22
Fully adjusted** Ref. 1.47 (0.94–2.30) 0.09
Nonadvanced PCay, no.
PCa cases/subcohort control participants 45/432 42/432 –
HR (95% CI)
Age and creatinine level adjusted Ref. 1.07 (0.66–1.72) 0.79
Fully adjusted ** Ref. 1.11 (0.67–1.82) 0.69
Advanced PCa§, no.
PCa cases/subcohort control participants 7/432 17/432 –
HR (95% CI)
Age and creatinine level adjusted Ref. 2.92 (1.00-8.56) 0.05
Fully adjusted** Ref. 4.04 (1.26-12.99) 0.02
Lethal PCa^, no.
PCa cases/subcohort control participants 4/432 14/432 –
HR (95% CI)
Age and creatinine level adjusted Ref. 4.39 (1.18–16.31) 0.03
Fully adjusted** Ref. 4.83 (1.26–18.45) 0.02
PCa = prostate cancer; HR = hazard ratio; CI = conﬁdence interval.
* 6-sulfatoxymelatonin (aMT6s) levels were dichotomized at the median in subcohort (17.14 ng/ml); HR compares low aMT6s levels (below the median) to
high levels (above the median).
** Fully adjusted model adjusted for age (as time scale), creatinine level, family history of PCa, history of depression, history of diabetes, severe sleep problems,
and current beta-blocker use.
yNonadvanced PCa deﬁned as less than stage T3a at diagnosis without distant metastases or death due to PCa.
§Advanced PCa deﬁned as stage T3a or T3b at diagnosis, distant metastases at diagnosis or death from PCa over follow-up.
^Lethal PCa deﬁned as distant metastases at diagnosis or death from PCa over follow-up.
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or starting follow-up 2 yr after urine collection, point
estimates remained similar but were not statistically
significant.
In this prospective study of older men, we found an
inverse association between urinary aMT6s levels and
advanced or lethal PCa. We are unaware of any prior
prospective evaluation of melatonin, as measured by its
urinary metabolite, and PCa, although the findings are
broadly in line with prior epidemiologic and experimental
studies. A study showed serum melatonin levels measured
over 24 h were lower in PCa patients than in controls [4].
Experimental studies suggest that melatonin has anticarci-
nogenic properties, as melatonin inhibits prostate tumor
growth in vitro and in vivo [3,7].
This study adds to accumulating epidemiologic data
investigating associations between circadian disruption or
sleep loss and PCa [2], and provides a potential mechanism
and framework for understanding prior results. Night-shift
work, which disrupts circadian rhythms and suppresses
melatonin secretion through nocturnal exposure to artifi-
cial light, was categorized as a probable human carcinogen
by the International Agency for Research on Cancer, based
primarily on data in breast cancer. Night-shift work has
been associated with increased risk of PCa [8] as well as
elevated prostate-specific antigen (PSA) levels among men
without PCa [9]. Moreover, blind men, some of whom may
have uninhibited melatonin secretion, have lower PCa
incidence compared to the general population [10].
Our results rest on a single morning urinary aMT6s
measurement, which may not represent long-term levels.We were also limited by a small number of events. Follow-
up is short andmenmay have had underlying disease at the
time of exposure assessment. We attempted to address
the possibility of reverse association, although power was
limited given the median follow-up time from urine
collection to diagnosis of 2.3 yr. Although we had broad
information on various covariates and were able to control
for possible confounders, we lacked information on factors
such as vitamin D levels. We also lacked information on
Gleason grade, screening history, or PSA levels, and stage
information was missing for 35% of cases. Finally, this
study was restricted to elderly men in Iceland; levels of
melatonin in this population may vary from those of other
populations, such as those with less extreme variation in
daylight during the year or younger men, although it is
noteworthy that levels did not vary by season of collection.
While this limits generalizability of our findings, it is
unlikely that underlying biologic impact on PCa pathogen-
esis would differ.
In summary,menwith lowermorning aMT6s levelswere
at increased risk for advanced or lethal PCa. These results
require replication in larger prospective cohort studies with
longer follow-up and more detailed clinical information.
Given that disruption of melatonin levels is potentially
avoidable, further studies of melatonin and PCa risk should
be a priority.
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